Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 14, 2024; 30(34): 3929-3931
Published online Sep 14, 2024. doi: 10.3748/wjg.v30.i34.3929
Published online Sep 14, 2024. doi: 10.3748/wjg.v30.i34.3929
Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis
Sara R Lopes, Claudio Martins, Madalena Teixeira, David Tomás, Department of Gastroen
Author contributions: Lopes SR and Martins C analyzed the data and wrote the manuscript; All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Claudio Martins, MD, Doctor, Department of Gastroenterology, Unidade Local de Saúde da Arrábida-Hospital de São Bernardo, Rua Camilo Castelo Branco, Setúbal 2910-446, Portugal. cmartins1@campus.ul.pt
Received: April 14, 2024
Revised: August 10, 2024
Accepted: August 23, 2024
Published online: September 14, 2024
Processing time: 148 Days and 21.2 Hours
Revised: August 10, 2024
Accepted: August 23, 2024
Published online: September 14, 2024
Processing time: 148 Days and 21.2 Hours
Core Tip
Core Tip: Tofacitinib, an oral small-molecule agent, has proven efficacy in inducing and maintaining remission among patients with moderate-to-severe ulcerative colitis. Real-world studies have showcased its effectiveness and safety profile to treat ulcerative colitis, primarily within Western countries. There have been a limited number of studies conducted on Asian patients.